Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (537)	5/20/2008 1:47:13 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

(The Forbes profile says Mr. Bowman is 74 years old, so although things look pretty bleak right now in terms of the shareprice and marketcap and that, this could just be part of retirement.) On May 14, 2008, Jack L. Bowman notified Targeted Genetics of his resignation as a member of the board of directors of Targeted Genetics effective May 15, 2008. Mr. Bowman's decision to resign is not related to any disagreement with Targeted Genetics or its management on any matter relating to its operations, policies or practices. Prior to his resignation, Mr. Bowman served as the chairman of the compensation committee of the board of directors and served on the Targeted Genetics board of directors since March 1997. Targeted Genetics greatly appreciates Mr. Bowman's service as a director and thanks him for his leadership contributions during that time. Pretty tough owning this stock for the past decade, although I suppose they get shares, they sell, they get more, they sell. -------------------- More important to TGEN right now is whether their expertise with AAV can be used for any new projects, or is this a platform that just isn't going to be useful. And especially whether the arthritis program has enough promise to perhaps pick up a partner and continue clinical trials. Also, if I go to the annual meeting, I might ask Parker whether the vaccine work is on the back burner--since she didn't mention it in the R&R presentation, I wonder about that. Huntington's ought to be offloaded to a new outfit like Ceregene--obviously they have enough projects and not enough money to persue more than one or two for the next year. Then poof I guess after that anyway.

To: Mike McFarland who wrote (537)	6/10/2008 1:52:30 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

(said nothing about the vaccine work) I have nothing new, but since I was poking around I'll park this here, something to do with their hiv vaccine work claims wipo.int Actually, the description tab is sorta interesting reading. wipo.int When the boost dose is administered by a rAAV vector, a single antigen of the pathogen may be administered with a single rAAV that encodes the antigen; two or multiple antigens of the pathogen may be administered with a single rAAV vector that encodes the two: or multiple antigens; or two or multiple antigens may be administered with two or multiple rAAV vectors the encode the antigens. When rAAV is used for boost, it is given as a single administration I don't see which of the tgen patents this one is associated with, but there is a list here patentstorm.us Everytime I tell myself I am stopped out of this awful stock, I find a reason just to move my mental stop down again, ha. It isn't actually funny how much I've lost on biotechs these past couple years, but at least I can afford the losses. I guess I am a little shellshocked that tgen has only a marketcap of $14M. You would not think that they could manage several different programs and that the cash will last for very long, but on the other hand you have to think that it would be a very trivial buyout possibility for any number of biotech companies--even the small biotechs that have a marketcap less than a billion could absorb tgen very easily and have several interesting projects for cheap.